NOTCH3半胱氨酸改变变异是台湾人群卒中重要危险因素
该研究基于台湾生物银行1517例基因组数据筛查NOTCH3半胱氨酸改变突变,并在7038名无卒中痴呆个体与800例缺血性卒中患者中基因分型。结果显示p.R544C突变在健康对照中占0.9%、缺血性卒中中占2.1%、小血管闭塞性卒中中占6.5%,校正血管危险因素后使总体卒中风险增加3.40倍、小血管闭塞性卒中风险增加11.05倍。
要点
- NOTCH3 p.R544C是台湾小血管闭塞性卒中的重要危险因素。
- 校正血管危险因素后p.R544C使总体卒中风险增加3.40倍、SVO卒中风险增加11.05倍。
- 携带p.R544C的无症状个体在59、66、67岁可见典型CADASIL广泛白质脑病。
核心结论
- NOTCH3 p.R544C变异是台湾小血管闭塞性卒中的重要危险因素。
- 携带NOTCH3突变个体的表型差异提示CADASIL存在疾病修饰因素。
研究设计与样本
- 查询含1517例台湾基因组序列的台湾生物银行,筛查致病性NOTCH3半胱氨酸改变突变。
- 在7038名无卒中痴呆个体和800例缺血性卒中患者中对参考人群所发现的NOTCH3突变进行基因分型。
- 比较两组NOTCH3基因分型、临床表现及MRI白质病变严重程度。
主要发现
- 从台湾生物银行鉴定出3个半胱氨酸改变NOTCH3变异:p.R544C、p.C853Y和p.C884Y。
- p.R544C在7038名健康对照中检出60例(0.9%),在800例缺血性卒中患者中检出17例(2.1%),在245例小血管闭塞性卒中患者中检出16例(6.5%)。
- 另外2个半胱氨酸改变突变极少检出。
- 校正血管危险因素后,携带p.R544C变异使总体卒中风险增加3.40倍(p=0.0001),使SVO卒中风险增加11.05倍(p=3.9×10-10)。
- 3例携带p.R544C的无症状个体在59、66、67岁时出现典型CADASIL的广泛白质脑病。
临床怎么用
- 在台湾缺血性卒中尤其小血管闭塞性卒中患者中应考虑NOTCH3 p.R544C检测。
- 对携带p.R544C的无症状个体应关注白质病变评估,即使高龄也可能表现亚临床。
- CADASIL表型差异提示需识别疾病修饰因素以指导风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test the hypothesis that the prevalence and clinical effect of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) have been underestimated in Asian populations. METHODS: The Taiwan Biobank, containing 1,517 Taiwanese genome sequences, was queried for pathogenic NOTCH3 cysteine-altering mutations. NOTCH3 mutations identified in the reference population were genotyped in 7,038 stroke- and dementia-free individuals and 800 patients with ischemic stroke. NOTCH3 genotyping, clinical manifestations, and the severity of white matter lesions on MRI were compared between the 2 groups. RESULTS: Three cysteine-altering NOTCH3 variants (p.R544C, p.C853Y, and p.C884Y) were identified from the Taiwan Biobank. We confirmed that the NOTCH3 p.R544C mutation was present in a significant number of individuals in Taiwan, including 60 of the 7,038 healthy controls (0.9%), 17 of the 800 patients with ischemic stroke (2.1%), and 16 of the 245 patients with small vessel occlusion (SVO) stroke (6.5%). The other 2 cysteine-altering mutations were rarely detected. After adjusting for vascular risk factors, harboring the p.R544C variant resulted in a 3.40-fold increased risk for overall stroke and an 11.05-fold increased risk for SVO stroke (p = 0.0001 and 3.9 × 10-10, respectively). Three symptom-free individuals carrying the p.R544C mutation had extensive leukoencephalopathy typical of CADASIL at age 59, 66, and 67, suggesting that p.R544C-related CADASIL could remain subclinical at advanced age. CONCLUSION: The NOTCH3 p.R544C variant is an important risk factor for SVO stroke in Taiwan. Phenotypic variation among individuals carrying a NOTCH3 mutation indicates the existence of disease-modifying factors in CADASIL.
引用
- Lee YC, Chung CP, Chang MH, et al. NOTCH3 cysteine-altering variant is an important risk factor for stroke in the Taiwanese population. Neurology. 2019. PMID: 31792094. doi:10.1212/WNL.0000000000008700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。